Welcome, Guest. Please login or register.
October 14, 2024, 08:23:48 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 233
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 178
Total: 178

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Company Halts Leading NASH Drug but Another Shows Promise  (Read 11597 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Company Halts Leading NASH Drug but Another Shows Promise
« on: December 09, 2020, 12:38:02 pm »
Genfit announced this week that it will stop the development of its non-alcoholic steatohepatitis (NASH) drug candidate elafibranor, which was in the running to become the first NASH therapy approved by the Food and Drug Administration (FDA).

NASH and its less severe form, non-alcoholic fatty liver disease (NAFLD), are responsible for a growing proportion of advanced liver disease. The buildup of fat in the liver triggers inflammation, which over time can lead to liver fibrosis, cirrhosis and liver cancer. With no effective medical therapies currently approved—and with several candidates recently missing the mark—management relies on lifestyle changes such as weight loss and exercise.

Read more...
https://www.hepmag.com/article/company-halts-leading-nash-drug-another-shows-promise

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.